GMILogo_Vertical-Gradient.png
Sleep Disorder Market revenue to cross USD 20.5 Bn by 2027: Global Market Insights Inc.
January 12, 2022 06:30 ET | Global Market Insights Inc.
Selbyville, Delaware, Jan. 12, 2022 (GLOBE NEWSWIRE) -- The sleep disorder market size is anticipated to record a valuation of USD 20.5 billion by 2027, according to the most recent study by...
Axsome Logo.png
Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 08, 2021 07:00 ET | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
AMR Logo.png
Global Narcolepsy Drugs Market Size to Hit $6.66 Billion by 2030: Allied Market Research
October 05, 2021 10:11 ET | Allied Market Research
Portland, OR, Oct. 05, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Narcolepsy Drugs Market was worth $2.68 billion in 2020, and is projected to...
Axsome Logo.png
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
September 16, 2021 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
TIP_link_300x300.jpg
Narcolepsy Market Growth Sturdy at 9.5% CAGR to Outstrip $4,537.9 Million by 2027 - COVID-19 Impact and Global Analysis by TheInsightPartners.com
May 18, 2021 19:25 ET | The Insight Partners
Pune, India., May 19, 2021 (GLOBE NEWSWIRE) -- Narcolepsy Market: Key InsightsAccording to our new research study on “Narcolepsy Market to 2027 – Global Analysis and Forecast – by Type, Product, and...
Graphical Research.jpg
Sleep Tech Devices Market Trends 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
May 10, 2021 06:00 ET | Graphical Research
Pune, India, May 10, 2021 (GLOBE NEWSWIRE) -- The global sleep tech devices market size is predicted to show tremendous growth during the forecast period owing to the growing need among...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting
September 21, 2020 07:00 ET | Axsome Therapeutics, Inc.
Single Phase 3 trial to be conducted to support an NDA filing of AXS-12 in the treatment of narcolepsy; trial initiation anticipated 1Q 2021 Extensive patient safety database, previously obtained...
axsomelogo-468x57.jpg
Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting
August 28, 2020 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
axsomelogo-468x57.jpg
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy
August 05, 2020 07:00 ET | Axsome Therapeutics, Inc.
Designation offers potential for expedited development and review FDA Orphan Drug Designation previously granted to Axsome for AXS-12 in narcolepsy Third FDA Breakthrough Therapy designation...
axsomelogo-468x57.jpg
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
July 30, 2020 07:00 ET | Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...